BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

Post-LOE

buprenorphine and naloxone

Gen Pharmaceuticals

ANDABUCCAL, SUBLINGUALFILM

Approved

Jun 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (buprenorphine and naloxone) by Gen Pharmaceuticals is naloxone. Approved for opioid dependence. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when…

Indications (1)

opioid dependence

Company

Worked on BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.